MBX Biosciences (MBX) Stock Price, News & Analysis

Company Overview

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

Key Stats

• Today's Range: $19.21 to $21.64
• 50-Day Range: $15.94 to $24.19
• 52-Week Range: $15.31 to $27.50
• Volume: 2.77 million shs
• Average Volume: 181,995 shs
• Market Capitalization: $680.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.25
• Consensus Rating: Buy

MBX Stock Analysis - Frequently Asked Questions

How have MBX shares performed this year?

MBX Biosciences' stock was trading at $21.00 at the start of the year. Since then, MBX shares have decreased by 3.0% and is now trading at $20.36.
View the best growth stocks for 2024 here.

How were MBX Biosciences' earnings last quarter?

MBX Biosciences, Inc. (NYSE:MBX) issued its quarterly earnings data on Thursday, November, 7th. The company reported ($2.78) EPS for the quarter, missing analysts' consensus estimates of ($2.72) by $0.06.

When did MBX Biosciences IPO?

MBX Biosciences (MBX) raised $163 million in an initial public offering (IPO) on Friday, September 13th 2024. The company issued 10,200,000 shares at a price of $16.00 per share.

When did the company's quiet period expire?

MBX Biosciences' quiet period expired on Wednesday, October 23rd. MBX Biosciences had issued 10,200,000 shares in its IPO on September 13th. The total size of the offering was $163,200,000 based on an initial share price of $16.00. During the company's quiet period, insiders and underwriters involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are MBX Biosciences' major shareholders?

MBX Biosciences' top institutional investors include Frazier Life Sciences Management L.P. (17.91%), NEA Management Company LLC (10.82%), Wellington Management Group LLP (8.79%) and RA Capital Management L.P. (4.52%). Insiders that own company stock include Life Sciences X LP Frazier and Edward T Mathers.
View institutional ownership trends.

How do I buy shares of MBX Biosciences?

Shares of MBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of MBX Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MBX Biosciences investors own include PepsiCo (PEP), Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN) and AstraZeneca (AZN).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NYSE:MBX
• Previous Symbol: NYSE:MBX
• CUSIP: N/A
• CIK: 1776111
• Web: mbxbio.com
• Phone: (317) 659-0200
• Fax: N/A
• Employees: 36
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $37.25
• High Stock Price Target: $44.00
• Low Stock Price Target: $30.00
• Potential Upside/Downside: +83.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,417,000
• Free Float: N/A
• Market Cap: $680.37 million
• Optionable: N/A
• Beta: N/A